Concurrent Radiotherapy with Paclitaxel and Cisplatin Chemotherapy for Stage Ⅲ Cervical Cancer Patients with Positive Pelvic Lymph Nodes
LI Cheng-hui;LONG Ting-ting;DUAN Ai-xiong;JIANG Qi-an;WANG Zhi-qiu;Affiliated Anqing Hospital of Anhui Medical University;
[Objective] To evaluate the clinical efficacy and toxicities of concurrent intensity modulated radiotherapy(IMRT) with paclitaxel and cisplatin chemotherapy for stage Ⅲ cervical carcinoma patients with positive pelvic lymph nodes. [Methods] Ninety patients with stage Ⅲ cervical cancer treated with concurrent IMRT and chemotherapy from April 2013 to April 2016 were enrolled,including 44 patients received paclitaxel and cisplatin for chemotherapy(combination group) and 46 patients received cisplatin monotherapy(monotherapy group). [Results] The effective rate in the combination group was higher than that in monotherapy group(97.73% vs 82.60%,P0.05). The 3 year-PFS of combination group was significantly higher than that of monotherapy group(29.55% vs 4.35%,P0.05). The incidence of Ⅲ/Ⅳ degree myelosuppression was 38.64%in combination group and 19.57% in monotherapy group(P0.05). The incidence of gastrointestinal reaction above Ⅲ degree of combination group and cisplatin group were 22.72% and 43.48%respectively(P0.05),weight loss was 28.26% in monotherapy group and 11.36% in combination group(P0.05). However,there was no difference in the incidence of reduced hemoglobin,radiation cystitis and radiation proctitis between two groups(P0.05). [Conclusion] Combination of paclitaxel and cisplatin is effective and safe in concurrent radiochemotherapy for stage Ⅲ cervical cancer patients with positive pelvic lymph nodes.